Merck to Test Promising HIV Vaccines Using NIAID Network

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 3
Volume 11
Issue 3

BETHESDA, Maryland-Merck & Co. will use a worldwide research network organized and funded by the National Institute of Allergy and Infectious Diseases (NIAID) to test promising HIV vaccines it develops.

BETHESDA, Maryland—Merck & Co. will use a worldwide research network organized and funded by the National Institute of Allergy and Infectious Diseases (NIAID) to test promising HIV vaccines it develops.

The agreement will enable Merck to evaluate its vaccines in a collaborative effort with the international HIV Vaccine Trials Network (HVTN), which consists of centers at 12 US academic sites and 13 institutions in Africa, Asia, South America, and the Caribbean.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.